Researcher Spotlight: Xu Cao, PhD City of Hope and Beckman Research Institute Many types of non-Hodgkin lymphoma (NHL) remain incurable due to its intrinsic genomic instability facilitating the escape from cytotoxic or targeted therapies. “Recent breakthroughs in understanding macrophage-mediated immune…
Researcher Spotlight: Natalie Grover, MD The University of North Carolina at Chapel Hill Although a majority of patients with Hodgkin lymphoma (HL) are cured with first-line therapy; about 15 percent of those patients experience primary refractory disease or relapse after…
Researcher Spotlight: Yong Gu Lee, PhD The Trustees of the University of Pennsylvania Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) and is the most common hematologic malignancy in the US. The prognosis…
Researcher Spotlight: Alexia Martinez de Paz, PhD Joan & Sanford I. Weill Medical College of Cornell University Cell-fate transitions (a biological process in which the function of a cell gets specialized, reprogrammed, or altered) during the germinal center (GC) reaction…
Researcher Spotlight: Laurianne Scourzic, PhD Joan & Sanford I. Weill Medical College of Cornell University Many B-cell lymphoma patients are resistant to, or relapse after, treatment. While researchers have demonstrated the causal role of cancer stem cells in the relapsing…
Researcher Spotlight: Paolo Strati, MD University of Texas M.D. Anderson Cancer Center Patients with relapsed or refractory large B-cell lymphoma (LBCL) treated with chimeric antigen receptor (CAR) T cells have increased their cure rate from 10 percent to 40 percent.…
Researcher Spotlight: Ryan Lynch, MD University of Washington Checkpoint inhibitors, a type of immunotherapy, have been approved for patients with relapsed Hodgkin lymphoma (HL); however, they do not lead to durable remissions in most patients. Dr. Lynch’s LRF grant project…
Researcher Spotlight: Adam Lin, MD, PhD Northwestern University Feinberg School of Medicine Many immunotherapies and cell therapies on the market have increased the cure rate for patients with non-Hodgkin lymphoma (NHL); however, the percentage of relapse and death continues to…